Posted by Matthew Mac Partlin on Monday, March 5, 2012

The use of Tranexamic Acid in truamatic haemorrage has been gaining increasing attention since the publication of the CRASH-II trial in 2010. Tranexamic acid (TXA) is an antifibrinolytic, meaning that it prevents the breakdown of clot that has already formed. This is different to the commonly used FFP and prothrombin complex concentrates (PCC), which provide clotting factors to facilitate clot formation and the much more expensive Factor ...
Continue reading ...